Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2001; 86(04): 942-944
DOI: 10.1055/s-0037-1616514
DOI: 10.1055/s-0037-1616514
Commentary
Continuous Infusion of Recombinant Factor VIIa: Continue or not?
Bruce M. Ewenstein
1
Hematology Division, Brigham & Women’s Hospital, Boston, MA, USA
› Author Affiliations
Further Information
Publication History
Publication Date:
09 December 2017 (online)
-
References
- 1 Scharrer I, Neutzling O. Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coagul Fibrinol 1993; 4: 753-8.
- 2 Ljung RC. Gene mutations and inhibitor formation in patients with haemophilia B. Acta Haematol 1995; 94 (Suppl. 01) 49-52.
- 3 Tuddenham EGD, Cooper DN. The molecular genetics of haemostasis and its inherited disorders. Oxford: Oxford University Press; 1994
- 4 Hay CRM. Why do inhibitors arise in patients with haemophilia A?. Brit J Haematol 1999; 105: 584-90.
- 5 Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM. Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to Factor VIII A multicenter therapeutic trial. New Engl J Med 1980; 303: 421-5.
- 6 Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, van Geijlswijk JL, van Houwelingen H, van Asten P, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
- 7 Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-8.
- 8 Hedner U, Glazer S, Pingel K. et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
- 9 Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-9.
- 10 Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant VIIa concentrate. Curr Opin Hematol 2000; 7: 408-13.
- 11 Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
- 12 Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. Haemophilia 1998; 4: 431-5.
- 13 Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86: 954-8.
- 14 Smith MP, Ludlam CA, Collins PW, Hay CRM, Wilde JT, Gringeri A, Melsen T, Savidge GF. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. Thromb Haemost 2001; 86: 949-53.
- 15 Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
- 16 Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 01) 118-23.
- 17 Hedner U. Dosing and monitoring of NovoSeven treatment. Haemostasis 1996; 26 (Suppl. 01) 102-6.
- 18 Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Brit J Haematol 1992; 82: 729-34.
- 19 Schulman S, d’Oiron R, Martinowitz U, Pasi J, Briquel M-E, MauserBunschoten E, Morfini M, Ritchie B, Goudemand J, Lloyd J, McPherson J, Négrier C, Peerlinck K, Petrini P, Tusell J. Experiences with continuous infusion of recombinant activated factor VII. Blood Coag Fibrinol 1998; 9 (Suppl. 01) S97-S101.
- 20 Mauser-Bunschoten EP, de Goede-Bolder A, Wielenga JJ, Levi M, Peer-linck K. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium. Neth J Med 1998; 53: 249-55.
- 21 Wildgoose P, Nemerson Y, Hansen LL, Nielsen FE, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 1992; 80: 25-8.
- 22 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
- 23 van’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generated by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-5.
- 24 ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass BL, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
- 25 Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of activated factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1998; 9 (Suppl. 01) S15-S20.
- 26 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
- 27 Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
- 28 Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinol 1998; 9 (Suppl. 01) S61-S5.
- 29 Rauch U, Bonderman D, Bohrmann B, Bodimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-5.
- 30 Torbert J. The thrombin activation pathway modulates the assembly, structure and lysis of human plasma clots in vitro. Thromb Haemost 1995; 73: 785-92.
- 31 Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86: 66-74.
- 32 Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinol 1998; 9 (Suppl. 01) 115-8.
- 33 Hansen LL, Nielsen FE, Hedner U. Validation of method for determination of recombinant FVIIa coagulant activity in plasma using a one-stage clotting assay [abstract]. Thromb Haemost 1993; 69: 865.
- 34 Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
- 35 Philippou H, Adami A, Amersey RA, Stubbs PJ, Lane DA. A novel specific immunoassay for plasma two-chain factor VIIa: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood 1997; 89: 767-75.